Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)
Trial details
- Registry ID
- NCT03940196
- Phase
- Phase 3
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)NCT03940196 | NVCR | Phase 3 | Completed | 2023-05-18Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |